Advertisement

Mesoblast Plunges as FDA Questions Cell-Therapy Manufacturing

Mesoblast Plunges as FDA Questions Cell-Therapy Manufacturing

The Australian stem-cell company will face some pointed questions from regulators about how it manufactures stem cells.